Core Viewpoint - The company Anbiping (688393.SH) announced that its shareholder Nanjing Qianjing plans to reduce its holdings by up to 1.5023 million shares, which represents no more than 1.61% of the company's total share capital [1] Group 1 - The reduction will occur through centralized bidding and block trading methods [1] - The maximum number of shares to be sold is specified as 1.5023 million [1] - This move indicates a potential shift in shareholder strategy or liquidity management [1]

Group 1 - The core point of the article is that the shareholder Nanjing Qianjing plans to reduce its holdings in the company Anbiping (688393.SH) through centralized bidding and block trading [1] - The total number of shares to be reduced is not more than 1.5023 million shares, which accounts for up to 1.61% of the company's current total share capital [1]

Core Viewpoint - Anbiping (688393.SH) announced that its shareholder, Nanjing Qianjing Venture Capital Partnership (Limited Partnership), plans to reduce its holdings in the company by up to 1.61% of the total share capital through centralized bidding and block trading methods [1] Group 1 - Nanjing Qianjing intends to reduce its shareholding by a maximum of 1.5 million shares, which represents 1.61% of the company's total share capital [1] - The reduction will occur in two phases: up to 935,700 shares (1.00% of total share capital) through centralized bidding and up to 566,700 shares (0.61% of total share capital) through block trading [1] - The share reduction will take place within three months after the announcement, starting 15 trading days from the date of the announcement [1]

证券代码：688393 证券简称：安必平 公告编号：2026-004 广州安必平医药科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 截至本公告披露日，南京乾靖创业投资合伙企业（有限合伙）（以下简称"南 京乾靖"）持有广州安必平医药科技股份有限公司（以下简称"公司"）1,502,343 股股份，占公司总股本的比例为 1.61%，该等股份为南京乾靖于公司首次公开发 行并上市前取得的股份，且已于 2021 年 8 月 20 日解除限售后上市流通。 减持计划的主要内容 因股东资金需求，南京乾靖拟通过集中竞价方式及大宗交易方式减持所持有 的公司股份不超过 1,502,343 股(含本数)，不超过公司目前总股本的 1.61%。其 中，通过集中竞价方式减持股份不超过 935,676 股(含本数)，不超过公司目前总 股本的 1.00%；通过大宗交易方式减持股份不超过 566,667 股(含本数)，不超过 公司目前总股本的 0.61%，上述减持自本公告披 ...

Group 1 - The core announcement states that Nanjing Qianjing Venture Capital Partnership holds approximately 1.5 million shares of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., accounting for 1.61% of the company's total share capital [1] - Nanjing Qianjing plans to reduce its holdings through centralized bidding and block trading, with a maximum reduction of 1.5 million shares, which is 1.61% of the total share capital [1] - The planned reduction includes up to approximately 940,000 shares through centralized bidding (1% of total share capital) and up to approximately 570,000 shares through block trading (0.61% of total share capital), to be executed within three months after the announcement [1]

Core Viewpoint - The medical device sector experienced a decline of 1.58% on January 16, with Kangzhong Medical leading the losses, while the Shanghai Composite Index fell by 0.26% and the Shenzhen Component Index decreased by 0.18% [1]. Group 1: Market Performance - The medical device sector's stocks showed mixed performance, with notable gainers including Huakang Clean (20.01% increase) and Yirui Technology (4.60% increase) [1]. - Conversely, Kangzhong Medical saw a significant drop of 8.60%, followed by Huada Zhizao with a decline of 6.61% [2]. - The overall trading volume in the medical device sector was substantial, with Huakang Clean achieving a transaction amount of 707 million yuan [1]. Group 2: Capital Flow - The medical device sector experienced a net outflow of 1.395 billion yuan from major funds, while retail investors contributed a net inflow of 1.42 billion yuan [2]. - Specific stocks like Huakang Clean had a net inflow of 58.17 million yuan from major funds, while retail investors showed a net outflow of 46.88 million yuan [3]. - The capital flow dynamics indicate a shift in investor sentiment, with retail investors actively participating despite the overall sector decline [2][3].

Group 1 - The core point of the news is that Anbiping's stock price dropped by 5.32% to 30.26 CNY per share, with a trading volume of 96.7 million CNY and a turnover rate of 3.33%, resulting in a total market capitalization of 2.831 billion CNY [1] - Anbiping, established on July 6, 2005, and listed on August 20, 2020, is primarily engaged in the research, production, and sales of in vitro diagnostic reagents and instruments [1] - The revenue composition of Anbiping includes 79.72% from self-produced products, 13.11% from purchased products, 5.90% from service income, and 1.27% from other sources [1] Group 2 - Longcheng Consumption Value Mixed A Fund (200006) is among the top ten circulating shareholders of Anbiping, holding 850,000 shares, which is unchanged from the previous period, representing 0.91% of the circulating shares [2] - The fund has incurred an estimated floating loss of approximately 1.445 million CNY today [2] - Longcheng Consumption Value Mixed A Fund was established on April 6, 2006, with a current scale of 516 million CNY, and has achieved a year-to-date return of 21.73%, ranking 56 out of 8,847 in its category [2]

Summary of the Conference Call for Anbiping Company Overview - **Company**: Anbiping - **Industry**: AI-assisted diagnostics in healthcare, specifically focusing on cervical cytology and pathology services Key Points and Arguments AI Model Development and Regulatory Progress - Anbiping's cervical cytology AI model has submitted a Class III medical device application, expected to be approved by the end of March or early April 2026, having completed over 6,000 clinical trials and published research in international journals, indicating strong competitiveness [2][5][11] - The company plans to implement a per-use charging model in the domestic market by the end of 2026 after obtaining the Class III certification, believing this model has greater market potential compared to a one-time purchase model [2][7] Market Opportunities and Policy Support - National policies support AI-assisted diagnostics being included in medical insurance, with local price increases for immunohistochemistry diagnostics observed in Chongqing, although the implementation varies by region [2][6] - The company is developing additional AI-enabled products in areas such as HE Pusang, gastric cancer, and breast cancer, with specific directions to be determined in the first half of 2026 [2][8] Financial Performance and Challenges - The overall business performance in 2025 is expected to be poor, with a downward trend in revenue due to the impact of HPV centralized procurement and an increase in VAT on certain product lines, affecting gross and net profit margins [3] - The direct sales to distribution transition has faced challenges, including price reductions and customer attrition, leading to declines in both revenue and profit [3] Revenue Growth and Projections - The revenue growth guidance for 2026 is approximately 20%, supported by low base effects, the clearing of HPV centralized procurement, and the gradual implementation of the direct sales to distribution strategy [4][25] - The pathology co-construction business aims to increase revenue from over 20 million yuan in 2025 to over 50 million yuan in 2026, with an expected growth rate of 40-50% [2][15] AI and Digital Solutions - The company is focusing on enhancing its digital solutions and plans to implement per-use charging at pathology co-construction points, aiming to integrate digital products into these locations [17][18] - Anbiping is also developing a pathology app similar to ChatGPT, targeting doctors, with a demo expected to launch in mid-2026 [10] Competitive Landscape and Future Outlook - The company currently does not see significant competition in its established pathology co-construction areas, which is favorable for its market position [19] - Anbiping is preparing for increased competition in the AI diagnostics market but remains focused on its product development and sales strategies [20][21] Financial Management and Investment Plans - The company plans to maintain a stable increase in net profit margins, targeting a long-term goal of 15%, although specific annual increases will require further assessment [30] - Investment in AI is expected to be lower in 2026 due to prior expenditures on computational resources, with a gradual increase anticipated as products enter clinical stages [27] Conclusion - 2025 is projected to be a challenging year for Anbiping, but the company aims to establish a solid foundation for the widespread application of its AI technologies in hospitals starting in 2026, ensuring sustainable business growth [31]

Core Insights - The 44th J.P. Morgan Healthcare Conference has highlighted significant industry developments, including a $1 billion investment by NVIDIA and Eli Lilly to establish a joint research lab in the San Francisco Bay Area to accelerate AI applications in the pharmaceutical sector [1] - The conference serves as a critical platform for domestic pharmaceutical companies to showcase core molecular product capabilities and advance overseas business development collaborations, indicating a return to global value validation for products [2] - The participation of over 8,000 global attendees and more than 500 listed companies underscores the strengthening global competitiveness of Chinese companies in the pharmaceutical sector [2] Group 1: Innovative Drugs - BeiGene focuses on oncology drug development and global commercialization, presenting progress on core products like CDK4 at the conference [2] - Rongchang Biologics has entered an exclusive licensing agreement with AbbVie for the novel PD-1/VEGF bispecific antibody drug RC148, granting AbbVie rights outside Greater China for development, production, and commercialization [2] - Hengrui Medicine, involved in the R&D, production, and sales of innovative and generic drugs, reported that over 50% of its revenue now comes from innovative drugs, with multiple self-developed products receiving approvals [2] Group 2: CRO/CMO - WuXi AppTec provides integrated CXO services covering the entire drug development and manufacturing process, projecting a 32.56% year-on-year growth in net profit for 2025 [3] - WuXi Biologics, specializing in biopharmaceutical CRDMO services, announced 209 new projects, bringing the total to 945, with potential milestone payments exceeding $4 billion from new research contracts [3] - Tigermed offers clinical trial CRO services and participated in the Asia-Pacific session of the conference, providing outsourcing services related to clinical trials for global pharmaceutical companies [3] Group 3: AI in Healthcare - NVIDIA and Eli Lilly's collaboration aims to build AI models to enhance new drug development, with a planned investment of $1 billion over the next five years [4] - RunDa Medical focuses on comprehensive medical testing services and is developing an automated testing interpretation system based on large models [4] - Anbiping has launched a digital pathology AI system and is exploring the registration and commercialization of AI medical devices in cervical cytology [4]

Summary of the Conference Call for Anbiping Company Overview - Anbiping is a company established in 2005, primarily engaged in the production of reagents and equipment in the pathology industry, with integrated capabilities across the supply chain [4][21] - The company has been involved in digital pathology since 2017 and launched the Aibinli APP, which has over 30,000 registered users [4] - Anbiping is the only company in the market that integrates formulations, equipment, scanners, and AI, positioning itself as a leader in cervical cytology AI certification [3][21] Industry and Market Position - Anbiping expects to obtain Class III certification for cervical cytology AI by late March to early April 2026, enhancing its market competitiveness [2] - Currently, only Saiweisen and Dean Diagnostics hold this certification, while Xiehe Medical College has it but has not promoted it [2] - The company aims to capture approximately 40% of the market share in cervical cytology AI [3][22] Financial Performance and Projections - In the first three quarters of 2025, Anbiping's performance declined due to factors such as HPV centralized procurement, VAT increases on the Fei's product line, and a shift from direct sales to distribution, leading to customer loss [5] - The revenue share from HPV is expected to drop from over 15% in 2024 to below 5% by the end of 2026 [5] - Anbiping is optimistic about returning to positive growth in 2026, with overall revenue guidance set at 20% and a net profit margin expected to be between 4-5% [2][15][6] Product and Service Insights - The company plans to set the added value of its upcoming Class III certification at around 100,000 yuan, contingent on market conditions [8] - Hospitals have provided positive feedback on Anbiping's cervical cytology AI product, noting its ease of use and efficiency, particularly among younger doctors [12] - The company is exploring a per-use charging model for its services, which could be facilitated by recent policy changes that require digital uploads of slides [9][10] Competitive Advantages - Anbiping is the only company that has publicly published clinical data supporting the accuracy and sensitivity of its products, which strengthens its market position [11] - The recent pathology medical service pricing guidelines favor the use of computer-aided diagnosis, which is expected to boost scanner sales [9] Future Strategies and Challenges - Anbiping anticipates growth in its immunohistochemistry and Fei's business lines by 20-30% in 2026, while LBC business growth is expected to be slower at 5-10% due to high competition [15] - The company aims to capture 20-30% of the immunohistochemistry market, focusing on replacing imported products [18] - Anbiping is also planning to launch new pathology AI products annually starting in 2028, with a focus on maintaining a competitive edge in the market [24] Regulatory and Market Dynamics - The company is aware that national guidelines may take time to be established, with a potential trial period in various provinces before finalizing policies [13] - Despite challenges, such as the need for doctors to adapt to domestic staining results, Anbiping sees opportunities for domestic product replacement in the pathology diagnosis field [19] Conclusion - Anbiping is positioned to leverage its unique capabilities in the AI pathology space, with a clear strategy for growth and market penetration, while navigating regulatory challenges and competitive pressures in the industry [24]